FOLH1 and prostate carcinoma: PSMA-targeted radioligand therapies have shown remarkable efficacy in the treatment of advanced metastatic prostate cancer, yet their uptake and retention in the salivary glands have been the source of dose-limiting toxicity related to severe xerostomia.7 It has been speculated that this uptake could be mediated by a cellular non-PSMA off-target.